Sümeyye Kodalak Cengiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sümeyye Kodalak Cengiz has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Burcu Öztürk Şahin
Department of Pulmonary Medicine, University of Health Sciences Gulhane School of Medicine Ankara, Türkiye
4 shared publications - Nurdan Kokturk
Department of Pulmonary Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey
3 shared publications - Sevda Şener Cömert
Department of Pulmonary Diseases, University of Health Sciences, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul, Turkey
3 shared publications - Umran Ozden Sertcelik
Department of Chest Diseases, Ankara Yıldırım Beyazıt University Faculty of Medicine, Ankara, Türkiye
3 shared publications - Alev Gurgun
Department of Chest Diseases Ege University Faculty of Medicine İzmir Türkiye
2 shared publications - Aylin Ozgen Alpaydin
Dokuz Eylul University
2 shared publications
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA5334
Troponin positivity outperforms clinical risk scores in young adults with pulmonary embolism: a 15-year retrospective study
Introduction: Pulmonary embolism (PE) in young adults is uncommon but clinically challenging, and prognostic tools are largely derived from older populations. We aimed to describe clinical characteristics and identify predictors of adverse outcomes in PE patients under 45 years of age. Methods: We retrospectively evaluated 147 consecutive patients aged 35 years). The primary composite adverse outcome included ICU admission, thrombolysis, invasive mechanical ventilation, or 30-day mortality. Independent prognostic predictors were assessed using multivariate logistic regression. Results: The cohort was predominantly male (69.4%), and 71.4% had at least one predisposing risk factor. Compared with patients ≤35 years, those >35 years had a higher prevalence of malignancy (p=0.034) and higher Wells (p=0.008) and PESI scores (p<0.001). Baseline laboratory parameters, including troponin levels, were comparable between age groups. Across multivariate models, troponin positivity consistently emerged as the strongest independent predictor of the composite adverse outcome (OR 14.43, 95% CI 3.51–59.32; p<0.001), independent of age and echocardiographic findings. In contrast, sPESI ≥1 showed only borderline prognostic significance (OR 7.75, p=0.058). Conclusion: In young adults with PE, troponin positivity provides substantial prognostic information beyond age and conventional clinical risk scores. Biomarker-based risk stratification may improve early risk assessment and management in this population.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA5334
Troponin positivity outperforms clinical risk scores in young adults with pulmonary embolism: a 15-year retrospective study
Introduction: Pulmonary embolism (PE) in young adults is uncommon but clinically challenging, and prognostic tools are largely derived from older populations. We aimed to describe clinical characteristics and identify predictors of adverse outcomes in PE patients under 45 years of age. Methods: We retrospectively evaluated 147 consecutive patients aged 35 years). The primary composite adverse outcome included ICU admission, thrombolysis, invasive mechanical ventilation, or 30-day mortality. Independent prognostic predictors were assessed using multivariate logistic regression. Results: The cohort was predominantly male (69.4%), and 71.4% had at least one predisposing risk factor. Compared with patients ≤35 years, those >35 years had a higher prevalence of malignancy (p=0.034) and higher Wells (p=0.008) and PESI scores (p<0.001). Baseline laboratory parameters, including troponin levels, were comparable between age groups. Across multivariate models, troponin positivity consistently emerged as the strongest independent predictor of the composite adverse outcome (OR 14.43, 95% CI 3.51–59.32; p<0.001), independent of age and echocardiographic findings. In contrast, sPESI ≥1 showed only borderline prognostic significance (OR 7.75, p=0.058). Conclusion: In young adults with PE, troponin positivity provides substantial prognostic information beyond age and conventional clinical risk scores. Biomarker-based risk stratification may improve early risk assessment and management in this population.
- Open Access
- 1 May 2026
- Published by King Faisal Specialist Hospital and Research Centre in Annals of Saudi Medicine
- Vol. 46 (3) , 225-233
Diagnostic utility and limitations of CT-guided transthoracic fine-needle aspiration biopsy in Lung-RADS 4 pulmonary nodules ≤2 cm
BACKGROUND: Managing small Lung-RADS 4 pulmonary nodules is clinically challenging. While CT-guided TTFNAB is standard, its efficacy and safety for lesions ≤2 cm require further evaluation to optimize outcomes and reduce unnecessary surgeries. OBJECTIVES: This study aimed to evaluate the diagnostic accuracy, safety, and factors influencing the outcomes of CT-guided TTFNAB in Lung-RADS category 4 pulmonary nodules measuring ≤2 cm. DESIGN: Retrospective study SETTING: Single-center, a tertiary referral center MATERIALS AND METHODS: A retrospective analysis was performed on 95 patients who underwent CT-guided TTFNAB between January 2021 and April 2024. Data included demographics, lesion characteristics (size, location, density, and pleural proximity), histopathological findings, and procedural outcomes. MAIN OUTCOME MEASURES: The primary endpoints were diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and factors influencing TTFNAB results, alongside procedural complications—specifically pneumothorax and chest tube requirement. SAMPLE SIZE: 95 patients RESULTS: Of the 95 nodules, 26 (27%) were benign and 69 (73%) were malignant according to TTFNAB. Final pathology confirmed 18 (19%) benign and 77 (81%) malignant lesions. All biopsies yielded sufficient material. Sensitivity, specificity, and overall diagnostic accuracy were 83%, 94%, and 89%, respectively. The PPV was 98%, while the NPV was 65%. Pleural thickening was significantly more frequent in both the TTFNAB benign group (38% vs. 13%, P =.006) and final benign diagnosis group (44% vs. 14%, P =.008). Pneumothorax occurred in 30% of cases, with 24% of these requiring chest tube drainage. No significant associations were found between diagnostic accuracy or complications and variables such as age, emphysema, Lung-RADS category, or nodule size. CONCLUSION: CT-guided TTFNAB is an effective diagnostic method for confirming malignancy in pulmonary nodules ≤2 cm classified as Lung-RADS 4, providing an overall accuracy of 89% and a PPV of 98%. However, a benign TTFNAB result cannot be considered diagnostically safe: the NPV of 65% and false-negative rate of 35% indicate that a negative biopsy does not reliably exclude malignancy. Clinicians must not rely on a negative result alone; close radiological follow-up or surgical biopsy is essential for these high-risk lesions. LIMITATIONS: The retrospective single-center design, small sample size, and limited generalizability. IRB APPROVAL NUMBER: 2024/010.99/6/23 (Date: 26.07.2024)
- 1 May 2026
- Published by King Faisal Specialist Hospital and Research Centre in Annals of Saudi Medicine
- Vol. 46 (3) , 225-233
Open AccessDiagnostic utility and limitations of CT-guided transthoracic fine-needle aspiration biopsy in Lung-RADS 4 pulmonary nodules ≤2 cm
BACKGROUND: Managing small Lung-RADS 4 pulmonary nodules is clinically challenging. While CT-guided TTFNAB is standard, its efficacy and safety for lesions ≤2 cm require further evaluation to optimize outcomes and reduce unnecessary surgeries. OBJECTIVES: This study aimed to evaluate the diagnostic accuracy, safety, and factors influencing the outcomes of CT-guided TTFNAB in Lung-RADS category 4 pulmonary nodules measuring ≤2 cm. DESIGN: Retrospective study SETTING: Single-center, a tertiary referral center MATERIALS AND METHODS: A retrospective analysis was performed on 95 patients who underwent CT-guided TTFNAB between January 2021 and April 2024. Data included demographics, lesion characteristics (size, location, density, and pleural proximity), histopathological findings, and procedural outcomes. MAIN OUTCOME MEASURES: The primary endpoints were diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and factors influencing TTFNAB results, alongside procedural complications—specifically pneumothorax and chest tube requirement. SAMPLE SIZE: 95 patients RESULTS: Of the 95 nodules, 26 (27%) were benign and 69 (73%) were malignant according to TTFNAB. Final pathology confirmed 18 (19%) benign and 77 (81%) malignant lesions. All biopsies yielded sufficient material. Sensitivity, specificity, and overall diagnostic accuracy were 83%, 94%, and 89%, respectively. The PPV was 98%, while the NPV was 65%. Pleural thickening was significantly more frequent in both the TTFNAB benign group (38% vs. 13%, P =.006) and final benign diagnosis group (44% vs. 14%, P =.008). Pneumothorax occurred in 30% of cases, with 24% of these requiring chest tube drainage. No significant associations were found between diagnostic accuracy or complications and variables such as age, emphysema, Lung-RADS category, or nodule size. CONCLUSION: CT-guided TTFNAB is an effective diagnostic method for confirming malignancy in pulmonary nodules ≤2 cm classified as Lung-RADS 4, providing an overall accuracy of 89% and a PPV of 98%. However, a benign TTFNAB result cannot be considered diagnostically safe: the NPV of 65% and false-negative rate of 35% indicate that a negative biopsy does not reliably exclude malignancy. Clinicians must not rely on a negative result alone; close radiological follow-up or surgical biopsy is essential for these high-risk lesions. LIMITATIONS: The retrospective single-center design, small sample size, and limited generalizability. IRB APPROVAL NUMBER: 2024/010.99/6/23 (Date: 26.07.2024)
- Open Access
- 13 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (7) , e47714
Risk factors, clinical features, and impact on survival of lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective study
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease, and lung cancer is a significant comorbidity with high prevalence and adverse impact on survival. Early detection of IPF and targeted interventions require understanding the associated risk factors and clinical presentation of lung cancer in IPF. This single-center, retrospective cohort study aimed to identify risk factors for lung cancer in IPF patients, investigate its clinical features, and determine its impact on survival. Of the 1481 patients with interstitial lung disease, 436 met the criteria for IPF per American Thoracic Society/European Respiratory Society guidelines. Patients followed up for P <.05), as also confirmed by multivariate analysis. Squamous cell carcinoma was the most common histological type (45.8%), with lower lobe predominance (59.3%) and peripheral location (78.0%). Most tumors (78.0%) were within or adjacent to fibrotic tissue. The median time from IPF diagnosis to lung cancer development was 2.80 years. The 0 to 3, 3 to 5, and >5-year mortality rates for patients with and without lung cancer were 15.2% to 3.3%, 35.5%- 8.4%, and 42.3% to 15.2%, respectively ( P = .026). Our study identified significant risk factors for lung cancer in IPF patients and demonstrated its negative impact on survival. The presence of emphysema, low body mass index, absence of antifibrotic therapy, and ≥36 pack-years of smoking were significantly associated with lung cancer development. Awareness of these factors is crucial for early diagnosis and appropriate treatment strategy determination, potentially improving outcomes in this high-risk population.
- 13 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (7) , e47714
Open AccessRisk factors, clinical features, and impact on survival of lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective study
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease, and lung cancer is a significant comorbidity with high prevalence and adverse impact on survival. Early detection of IPF and targeted interventions require understanding the associated risk factors and clinical presentation of lung cancer in IPF. This single-center, retrospective cohort study aimed to identify risk factors for lung cancer in IPF patients, investigate its clinical features, and determine its impact on survival. Of the 1481 patients with interstitial lung disease, 436 met the criteria for IPF per American Thoracic Society/European Respiratory Society guidelines. Patients followed up for P <.05), as also confirmed by multivariate analysis. Squamous cell carcinoma was the most common histological type (45.8%), with lower lobe predominance (59.3%) and peripheral location (78.0%). Most tumors (78.0%) were within or adjacent to fibrotic tissue. The median time from IPF diagnosis to lung cancer development was 2.80 years. The 0 to 3, 3 to 5, and >5-year mortality rates for patients with and without lung cancer were 15.2% to 3.3%, 35.5%- 8.4%, and 42.3% to 15.2%, respectively ( P = .026). Our study identified significant risk factors for lung cancer in IPF patients and demonstrated its negative impact on survival. The presence of emphysema, low body mass index, absence of antifibrotic therapy, and ≥36 pack-years of smoking were significantly associated with lung cancer development. Awareness of these factors is crucial for early diagnosis and appropriate treatment strategy determination, potentially improving outcomes in this high-risk population.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 3993-4003
Validation Study of Rome Criteria for Assessing COPD Exacerbation Severity and Predicting Clinical Outcomes: Turkish Thoracic Society COPD Assembly
Objective: The Rome classification was introduced to assess the severity of acute exacerbation (AE) of chronic obstructive pulmonary disease (COPD) based on easily measurable variables. However, its validation for global use has not yet reached a sufficient level. This study aims to evaluate the validity of the Rome criteria in determining the severity and prognosis of COPD AE in Turkey. Methods: This multicenter study, conducted for the first time in Turkey and for the fourth time worldwide, included 750 patients diagnosed with AE-COPD who presented to emergency departments and outpatient clinics. According to the Rome criteria, patients were classified into three groups: mild, moderate, and severe AE-COPD. Results: The study included 99 (13.2%) patients in the mild, 479 (63.9%) in the moderate, and 172 (22.9%) in the severe group. Emergency visits, hospitalizations, and ICU admissions in the past year were more frequent in the moderate and severe groups (p < 0.001 for all comparisons). Regarding outcomes of emergency or outpatient visits, most mild exacerbation cases were discharged (p < 0.001), while most moderate and severe exacerbations required hospitalization (p < 0.001). Compared to the moderate group, the severe exacerbation group had a higher risk of ICU admission (p < 0.001), NIV (p < 0.001), IMV (p < 0.001), in-hospital mortality (p < 0.001), and 30-day mortality (p = 0.015). No significant differences were found in 90-day mortality or 30 and 90-day readmission rates (p = 0.258, p = 0.712, p = 0.681, respectively). Survival analysis revealed no significant difference between the moderate and severe groups (p = 0.764). Conclusion: The findings suggest that the Rome criteria can be successfully used to assess exacerbation severity in AE-COPD patients presenting to secondary and tertiary care hospitals in Turkey.
- 1 December 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 3993-4003
Open AccessValidation Study of Rome Criteria for Assessing COPD Exacerbation Severity and Predicting Clinical Outcomes: Turkish Thoracic Society COPD Assembly
Objective: The Rome classification was introduced to assess the severity of acute exacerbation (AE) of chronic obstructive pulmonary disease (COPD) based on easily measurable variables. However, its validation for global use has not yet reached a sufficient level. This study aims to evaluate the validity of the Rome criteria in determining the severity and prognosis of COPD AE in Turkey. Methods: This multicenter study, conducted for the first time in Turkey and for the fourth time worldwide, included 750 patients diagnosed with AE-COPD who presented to emergency departments and outpatient clinics. According to the Rome criteria, patients were classified into three groups: mild, moderate, and severe AE-COPD. Results: The study included 99 (13.2%) patients in the mild, 479 (63.9%) in the moderate, and 172 (22.9%) in the severe group. Emergency visits, hospitalizations, and ICU admissions in the past year were more frequent in the moderate and severe groups (p < 0.001 for all comparisons). Regarding outcomes of emergency or outpatient visits, most mild exacerbation cases were discharged (p < 0.001), while most moderate and severe exacerbations required hospitalization (p < 0.001). Compared to the moderate group, the severe exacerbation group had a higher risk of ICU admission (p < 0.001), NIV (p < 0.001), IMV (p < 0.001), in-hospital mortality (p < 0.001), and 30-day mortality (p = 0.015). No significant differences were found in 90-day mortality or 30 and 90-day readmission rates (p = 0.258, p = 0.712, p = 0.681, respectively). Survival analysis revealed no significant difference between the moderate and severe groups (p = 0.764). Conclusion: The findings suggest that the Rome criteria can be successfully used to assess exacerbation severity in AE-COPD patients presenting to secondary and tertiary care hospitals in Turkey.
- Open Access
- 16 June 2025
- Published by Wolters Kluwer Health in Annals of Thoracic Medicine
- Vol. 20 (3) , 176-182
Conformity of spirometric tests with acceptability criteria and assessment of confounding factors in routine clinical practice
BACKGROUND: Spirometry is one of the basic methods used in the diagnosis, treatment, and follow-up of respiratory disease. Spirometric test results that do not comply with international standards may be misinterpreted and lead to misdiagnosis and treatment. We aimed to assess the tests of patients that meet the “American Thoracic Society/European Respiratory Society (ATS/ERS) 2019” recommendations, to identify the most common errors, and to explore patient characteristics possibly associated with failure to reach these standards. METHODS: A total of 1000 spirometries performed between January and December 2023 were randomly selected retrospectively. Spirometric maneuvers were evaluated for meeting the acceptability criteria of the ATS/ERS 2019 guidelines. RESULTS: The acceptability spirometry rate was 62.5%. The most frequently unmet criterion was failure to meet any of the three ends of forced expiration at 20.7%. There was no significant difference between male and female in terms of the acceptability of maneuvers. The 45–59 and 60–74 age groups were statistically more significant than the younger and older. Smoking, diagnosis of chronic obstructive pulmonary disease, and number of spirometry practices were significantly associated with conformity to test acceptability criteria. The forced expiratory volume in 1 second (FEV1) divided by the forced vital capacity, FEV1, and forced expiratory times had a statistically significant independent effect on the acceptability of spirometric maneuvers. CONCLUSION: Nearly one-third of the tests performed by an experienced technician in a tertiary care hospital did not meet the acceptability criteria. Our study shows the importance of the learnability of maneuvers through repeated spirometry experiences.
- 16 June 2025
- Published by Wolters Kluwer Health in Annals of Thoracic Medicine
- Vol. 20 (3) , 176-182
Open AccessConformity of spirometric tests with acceptability criteria and assessment of confounding factors in routine clinical practice
BACKGROUND: Spirometry is one of the basic methods used in the diagnosis, treatment, and follow-up of respiratory disease. Spirometric test results that do not comply with international standards may be misinterpreted and lead to misdiagnosis and treatment. We aimed to assess the tests of patients that meet the “American Thoracic Society/European Respiratory Society (ATS/ERS) 2019” recommendations, to identify the most common errors, and to explore patient characteristics possibly associated with failure to reach these standards. METHODS: A total of 1000 spirometries performed between January and December 2023 were randomly selected retrospectively. Spirometric maneuvers were evaluated for meeting the acceptability criteria of the ATS/ERS 2019 guidelines. RESULTS: The acceptability spirometry rate was 62.5%. The most frequently unmet criterion was failure to meet any of the three ends of forced expiration at 20.7%. There was no significant difference between male and female in terms of the acceptability of maneuvers. The 45–59 and 60–74 age groups were statistically more significant than the younger and older. Smoking, diagnosis of chronic obstructive pulmonary disease, and number of spirometry practices were significantly associated with conformity to test acceptability criteria. The forced expiratory volume in 1 second (FEV1) divided by the forced vital capacity, FEV1, and forced expiratory times had a statistically significant independent effect on the acceptability of spirometric maneuvers. CONCLUSION: Nearly one-third of the tests performed by an experienced technician in a tertiary care hospital did not meet the acceptability criteria. Our study shows the importance of the learnability of maneuvers through repeated spirometry experiences.
- 28 March 2025
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 49 (1) , 1-6
The Effect of Plasma Osmolality on Prognosis in Non-Massive Pulmonary Embolism
Objective: Plasma osmolality provides insight into fluid and electrolyte balance and can serve as a prognostic marker in critically ill patients. There is limited research on the relationship between plasma osmolality and mortality in pulmonary embolism (PE). The potential role of plasma osmolality in predicting mortality in PE patients is examined in this study. Methods: A retrospective analysis was conducted on patients admitted to the chest diseases ward with acute PE. Data on demographics, comorbidities, clinical and laboratory results, in-hospital mortality, and 30-day mortality were collected. Plasma osmolality was calculated using sodium, plasma glucose, and blood urea nitrogen (BUN) levels at admission. Patients were categorized into hyposmolality, normosmolality, and hyperosmolality groups. Results: The study included 226 patients (100 males, 44.2%), aged 23-90 years. In-hospital mortality occurred in 13 patients (5.8%). The mortality rate was significantly higher in patients with a simplified Pulmonary Embolism Severity Index score ≥1 (P = .031). In addition, lower albumin levels (P = .008) and higher BUN (P = .007) and urea levels (P = .005) were significantly associated with in-hospital mortality. No significant differences in D-dimer, creatinine, glucose, sodium, and osmolality levels were observed between patients who were discharged and those who experienced in-hospital mortality. Mortality rates within 30 days did not significantly differ across osmolality groups (P > .05). Conclusion: This study did not find a significant correlation between plasma osmolality and short-term mortality in patients with acute PE.Cite this article as: Eraslan BZ, Kodalak-Cengiz S, İçmeli ÖS, Kiral N, Şener-Cömert S. The effect of plasma osmolality on prognosis in non-massive pulmonary embolism. Cerrahpaşa Med J. 2025; 49, 0050, doi: 10.5152/cjm.2025.24050.
- 28 March 2025
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 49 (1) , 1-6
The Effect of Plasma Osmolality on Prognosis in Non-Massive Pulmonary Embolism
Objective: Plasma osmolality provides insight into fluid and electrolyte balance and can serve as a prognostic marker in critically ill patients. There is limited research on the relationship between plasma osmolality and mortality in pulmonary embolism (PE). The potential role of plasma osmolality in predicting mortality in PE patients is examined in this study. Methods: A retrospective analysis was conducted on patients admitted to the chest diseases ward with acute PE. Data on demographics, comorbidities, clinical and laboratory results, in-hospital mortality, and 30-day mortality were collected. Plasma osmolality was calculated using sodium, plasma glucose, and blood urea nitrogen (BUN) levels at admission. Patients were categorized into hyposmolality, normosmolality, and hyperosmolality groups. Results: The study included 226 patients (100 males, 44.2%), aged 23-90 years. In-hospital mortality occurred in 13 patients (5.8%). The mortality rate was significantly higher in patients with a simplified Pulmonary Embolism Severity Index score ≥1 (P = .031). In addition, lower albumin levels (P = .008) and higher BUN (P = .007) and urea levels (P = .005) were significantly associated with in-hospital mortality. No significant differences in D-dimer, creatinine, glucose, sodium, and osmolality levels were observed between patients who were discharged and those who experienced in-hospital mortality. Mortality rates within 30 days did not significantly differ across osmolality groups (P > .05). Conclusion: This study did not find a significant correlation between plasma osmolality and short-term mortality in patients with acute PE.Cite this article as: Eraslan BZ, Kodalak-Cengiz S, İçmeli ÖS, Kiral N, Şener-Cömert S. The effect of plasma osmolality on prognosis in non-massive pulmonary embolism. Cerrahpaşa Med J. 2025; 49, 0050, doi: 10.5152/cjm.2025.24050.
- Open Access
- 6 December 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 26 (1) , 150-158
Red cell distribution width to albumin ratio and mortality in acute pulmonary thromboembolism
The red cell distribution width (RDW)/albumin ratio (RAR) is an inflammation-based prognostic biomarker. To date, its prognostic value in patients with pulmonary thromboembolism (PTE) has been investigated in only one study. This study aimed to assess the effect of RAR on mortality in patients with PTE. Patients admitted for PTE between 2017 and 2023 were retrospectively reviewed. The data collected included demographic information, comorbidities, clinical findings, RDW, albumin, troponin, D-dimer levels, and in-hospital and 30-day mortality outcomes. RAR was calculated by dividing the RDW by albumin. A total of 190 patients were included in the study, of whom 83 (43.7%) were male. The mean age was 63 years (range: 23–89), and the mean RAR was 4.48% ± 1.68% /g/dL. A positive correlation was observed between RAR and both age and troponin level, whereas inverse correlations were noted with systolic blood pressure (sBP), diastolic blood pressure (dBP), and oxygen saturation (SpO2). Using a cutoff value of 5.294 determined by ROC analysis, patients with RAR ≥ 5.294 had a significantly shorter mean survival time than those with RAR value < 5.294 (16.310 months vs 35.163 months; log-rank test, P < 0.001). Multivariate Cox regression analysis identified malignancy (hazard ratio [HR], 4.213; 95% confidence interval [CI], 1.103–16.090; P = 0.035) and RAR (HR: 1.295, 95% CI: 1.035–1.621, P = 0.024) as independent predictors of survival. In conclusion, an RAR value ≥ 5.294 was associated with significantly shorter survival, underscoring its potential utility as a prognostic marker in clinical practice for non-massive PTE.
- 6 December 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 26 (1) , 150-158
Open AccessRed cell distribution width to albumin ratio and mortality in acute pulmonary thromboembolism
The red cell distribution width (RDW)/albumin ratio (RAR) is an inflammation-based prognostic biomarker. To date, its prognostic value in patients with pulmonary thromboembolism (PTE) has been investigated in only one study. This study aimed to assess the effect of RAR on mortality in patients with PTE. Patients admitted for PTE between 2017 and 2023 were retrospectively reviewed. The data collected included demographic information, comorbidities, clinical findings, RDW, albumin, troponin, D-dimer levels, and in-hospital and 30-day mortality outcomes. RAR was calculated by dividing the RDW by albumin. A total of 190 patients were included in the study, of whom 83 (43.7%) were male. The mean age was 63 years (range: 23–89), and the mean RAR was 4.48% ± 1.68% /g/dL. A positive correlation was observed between RAR and both age and troponin level, whereas inverse correlations were noted with systolic blood pressure (sBP), diastolic blood pressure (dBP), and oxygen saturation (SpO2). Using a cutoff value of 5.294 determined by ROC analysis, patients with RAR ≥ 5.294 had a significantly shorter mean survival time than those with RAR value < 5.294 (16.310 months vs 35.163 months; log-rank test, P < 0.001). Multivariate Cox regression analysis identified malignancy (hazard ratio [HR], 4.213; 95% confidence interval [CI], 1.103–16.090; P = 0.035) and RAR (HR: 1.295, 95% CI: 1.035–1.621, P = 0.024) as independent predictors of survival. In conclusion, an RAR value ≥ 5.294 was associated with significantly shorter survival, underscoring its potential utility as a prognostic marker in clinical practice for non-massive PTE.
- Open Access
- 29 November 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (48) , e40483
Readmission rates within the first 30 and 90 days after severe COPD exacerbations (RACE study)
Chronic obstructive pulmonary disease (COPD) frequently results in hospital readmission and contributes to increased morbidity and mortality. This multicenter prospective study aimed to identify factors that increase the risk of readmission within 30 to 90 days of severe COPD exacerbation. A total of 415 patients admitted to the emergency department (ED) or general pulmonology ward after discharge due to severe exacerbations from 13 tertiary centers in Turkey were included. Of the participants, 346 (83.4%) were male and 69 (16.6%) were female, with an average age of 69.0 ± 9.1 years. Readmissions within 30 and 90 days after the initial hospitalization occurred in 176 (42.4%) and 191 (46%) patients, respectively. Prospective data collection focused on exacerbation severity, disease severity, and the utility of initial admissions. Factors for 30 to 90 day readmission were analyzed using univariate and multivariate regression models. A 30-day readmission correlated significantly with Hospital Anxiety Depression Scale scores above 16 [odds ratio [OR] 95% confidence intervals [CI]: 1.9 (1.1–3.6); P = .042], severe exacerbation history in the previous year [OR 95% CI: 1.7 (1.1–2.9); P = .038], hospital-acquired pneumonia [OR 95% CI: 1.9 (1–4.1); P = .049)], and frequent antibiotic use in the previous year [OR 95% CI: 1.8 (1.2–2.7); P = .007]. Risk factors for 90-day readmissions included: Grades 3 to 4 tricuspid regurgitation [OR 95% CI: 2.2 (1.1–4.4); P = .024], 2 or more moderate COPD exacerbations [OR 95% CI: 1.9 (1.2–3.1); P = .010], severe exacerbation history in the previous year [OR 95% CI: 2.5 (1.5–4.2); P = .001], immunosuppression [OR 95% CI: 2.7 (1.2–5.7); P = .013], frequent antibiotic use the previous year [OR 95% CI: 1.5 (1–2.4); P = .048], hospitalization via the ED [OR 95% CI: 1.6 (1.1–2.6); P = .028]. To mitigate complications and readmissions, patients with a history of frequent severe COPD exacerbations, high anxiety and depression scores, frequent antibiotic requirements, immunosuppression, tricuspid regurgitation, hospital-acquired pneumonia, and those admitted to the ED should be prioritized for remote monitoring after initial discharge.
- 29 November 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (48) , e40483
Open AccessReadmission rates within the first 30 and 90 days after severe COPD exacerbations (RACE study)
Chronic obstructive pulmonary disease (COPD) frequently results in hospital readmission and contributes to increased morbidity and mortality. This multicenter prospective study aimed to identify factors that increase the risk of readmission within 30 to 90 days of severe COPD exacerbation. A total of 415 patients admitted to the emergency department (ED) or general pulmonology ward after discharge due to severe exacerbations from 13 tertiary centers in Turkey were included. Of the participants, 346 (83.4%) were male and 69 (16.6%) were female, with an average age of 69.0 ± 9.1 years. Readmissions within 30 and 90 days after the initial hospitalization occurred in 176 (42.4%) and 191 (46%) patients, respectively. Prospective data collection focused on exacerbation severity, disease severity, and the utility of initial admissions. Factors for 30 to 90 day readmission were analyzed using univariate and multivariate regression models. A 30-day readmission correlated significantly with Hospital Anxiety Depression Scale scores above 16 [odds ratio [OR] 95% confidence intervals [CI]: 1.9 (1.1–3.6); P = .042], severe exacerbation history in the previous year [OR 95% CI: 1.7 (1.1–2.9); P = .038], hospital-acquired pneumonia [OR 95% CI: 1.9 (1–4.1); P = .049)], and frequent antibiotic use in the previous year [OR 95% CI: 1.8 (1.2–2.7); P = .007]. Risk factors for 90-day readmissions included: Grades 3 to 4 tricuspid regurgitation [OR 95% CI: 2.2 (1.1–4.4); P = .024], 2 or more moderate COPD exacerbations [OR 95% CI: 1.9 (1.2–3.1); P = .010], severe exacerbation history in the previous year [OR 95% CI: 2.5 (1.5–4.2); P = .001], immunosuppression [OR 95% CI: 2.7 (1.2–5.7); P = .013], frequent antibiotic use the previous year [OR 95% CI: 1.5 (1–2.4); P = .048], hospitalization via the ED [OR 95% CI: 1.6 (1.1–2.6); P = .028]. To mitigate complications and readmissions, patients with a history of frequent severe COPD exacerbations, high anxiety and depression scores, frequent antibiotic requirements, immunosuppression, tricuspid regurgitation, hospital-acquired pneumonia, and those admitted to the ED should be prioritized for remote monitoring after initial discharge.
- Open Access
- 10 January 2024
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 25 (1) , 17-25
Factors Associated with Increasing Costs in Severe Chronic Obstructive Pulmonary Disease Exacerbation: Turkish Thoracic Society Chronic Obstructive Pulmonary Disease Assembly
COPD,severe exacerbation,costs,discharge,antibiotic,nutrition,pulmonary rehabilitation
- 10 January 2024
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 25 (1) , 17-25
Open AccessFactors Associated with Increasing Costs in Severe Chronic Obstructive Pulmonary Disease Exacerbation: Turkish Thoracic Society Chronic Obstructive Pulmonary Disease Assembly
COPD,severe exacerbation,costs,discharge,antibiotic,nutrition,pulmonary rehabilitation
- Open Access
- 1 January 2024
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2024 (1)
The Role of Anxiety Scales and Serum Copeptin Levels in Determining the Preprocedure Anxiety Status of Patients Who Undergo Fiberoptic Bronchoscopy and Endobronchial Ultrasonography
Introduction. Fiberoptic bronchoscopy (FOB) and endobronchial ultrasonography (EBUS) are safe and frequently used minimally invasive procedures. However, the decision to undergo an interventional procedure causes anxiety development and negative consequences in the individual. Objective. To determine the role of the State‐Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), visual analog scale (VAS), and serum copeptin levels, their sensitivity, specificity, and the correlation between them in the anxiety levels of patients before undergoing FOB and EBUS. Method. A total of 219 patients who were scheduled to undergo FOB/EBUS were included in this prospective observational study. Demographic data were recorded. Patients’ anxiety levels before the procedure were evaluated using STAI‐SA, STAI‐TA, BAI, and VAS. Copeptin levels were measured before and after the procedure. Results. Patients were moderately anxious according to STAI‐SA, STAI‐TA, and VAS and were mildly anxious according to the BAI. Women and patients aged under 65 years were significantly more anxious. All scales were positively correlated. Serum copeptin levels before the procedure were 5.8 ± 4.8 and 4.3 ± 3.9 ng/mL afterwards, with a significant difference between them. The specificity and sensitivity of VAS were found to be the highest. Conclusion. All anxiety scales are correlated with each other, and we recommend VAS as a powerful alternative for determining anxiety levels in terms of easier understanding and implementation. Serum copeptin levels before the procedure were significantly higher than afterwards and may be used as a potential biomarker for preprocedural anxiety.
- 1 January 2024
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2024 (1)
Open AccessThe Role of Anxiety Scales and Serum Copeptin Levels in Determining the Preprocedure Anxiety Status of Patients Who Undergo Fiberoptic Bronchoscopy and Endobronchial Ultrasonography
Introduction. Fiberoptic bronchoscopy (FOB) and endobronchial ultrasonography (EBUS) are safe and frequently used minimally invasive procedures. However, the decision to undergo an interventional procedure causes anxiety development and negative consequences in the individual. Objective. To determine the role of the State‐Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), visual analog scale (VAS), and serum copeptin levels, their sensitivity, specificity, and the correlation between them in the anxiety levels of patients before undergoing FOB and EBUS. Method. A total of 219 patients who were scheduled to undergo FOB/EBUS were included in this prospective observational study. Demographic data were recorded. Patients’ anxiety levels before the procedure were evaluated using STAI‐SA, STAI‐TA, BAI, and VAS. Copeptin levels were measured before and after the procedure. Results. Patients were moderately anxious according to STAI‐SA, STAI‐TA, and VAS and were mildly anxious according to the BAI. Women and patients aged under 65 years were significantly more anxious. All scales were positively correlated. Serum copeptin levels before the procedure were 5.8 ± 4.8 and 4.3 ± 3.9 ng/mL afterwards, with a significant difference between them. The specificity and sensitivity of VAS were found to be the highest. Conclusion. All anxiety scales are correlated with each other, and we recommend VAS as a powerful alternative for determining anxiety levels in terms of easier understanding and implementation. Serum copeptin levels before the procedure were significantly higher than afterwards and may be used as a potential biomarker for preprocedural anxiety.